# A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis

> **NCT05646381** · PHASE2 · RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 502 (estimated)

## Conditions studied

- Aortic Stenosis

## Interventions

- **DRUG:** Pelacarsen (TQJ230) 80mg
- **DRUG:** Matching placebo

## Key facts

- **NCT ID:** NCT05646381
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-07
- **Primary completion:** 2030-03-12
- **Final completion:** 2030-03-12
- **Target enrollment:** 502 (ESTIMATED)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05646381

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05646381, "A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05646381. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*